BEGIN:VCALENDAR
PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN
VERSION:2.0
BEGIN:VEVENT
DESCRIPTION:The 6th Rare and Genetic Kidney Disease Drug Development Summi
 t is the industry's only meeting dedicated exclusively to advancing thera
 pies across IgAN\, FSGS\, ADPKD\, Alport syndrome\, C3G\, and related ren
 al indications. Bringing together leaders from biopharma\, academia\, and
  patient advocacy\, this summit spans discovery through commercialization
  to support smarter\, faster decision-making across kidney disease pipeli
 nes.\n\nAs competition intensifies in rare and genetic kidney disease dru
 g development\, companies are under increasing pressure to differentiate 
 assets\, generate robust clinical evidence\, and accelerate timelines to 
 patients. Accelerated approval pathways have fundamentally reshaped how t
 eams approach target evaluation\, surrogate endpoint selection\, and tria
 l design within small\, heterogeneous patient populations. With more prog
 rams progressing into mid- and late-stage development than ever before\, 
 the stakes for getting these decisions right have never been higher.At th
 e same time\, persistent challenges in patient recruitment\, uncertainty 
 around clinically meaningful surrogate endpoints\, and incomplete mechani
 stic understanding continue to slow trials and increase risk. To move the
  field forward\, teams must adopt more precise patient stratification str
 ategies\, build stronger translational models\, and optimize trial design
 s that balance scientific rigor with operational feasibility.\n\nThis yea
 r's summit convenes experts from organizations advancing approved and lat
 e-stage therapies\, including Novartis\, Calliditas\, and Travere Therape
 utics\, to share real-world data\, pressure-test development strategies\,
  and benchmark approaches across the renal landscape. Attendees will gain
  practical insights into novel target validation\, endpoint selection\, a
 nd patient-focused trial design that can be applied directly to ongoing a
 nd future programs.\n\nJoin the community shaping the next generation of 
 kidney disease therapies and leave with actionable strategies to advance 
 promising assets from discovery to patients.\n\nURLs:Website:&nbsp\;https
 ://go.evvnt.com/3590343-0?pid=185Tickets:&nbsp\;https://go.evvnt.com/3590
 343-2?pid=185Brochure:&nbsp\;https://go.evvnt.com/3590343-3?pid=185\n\nPr
 ices:Drug Developer Pricing - Conference + 3 Workshops: USD 4397.00\,Drug
  Developer Pricing - Conference Only: USD 3099.00\,Academic Pricing - Con
 ference + 3 Workshops: USD 3797.00\,Academic Pricing - Conference Only: U
 SD 2699.00\,Service Provider Pricing - Conference + 3 Workshops: USD 5297
 .00\,Service Provider Pricing - Conference Only: USD 3799.00\n\nSpeakers:
 &nbsp\;Savithri Kota\, Director\, Precision Nephrology\, Bayer\, Jennifer
  McKenzie\, Senior Clinical Program Leader\, Boehringer Ingelheim\, Srini
  Srinivas\, Senior Medical\, Director Novartis\, Kristin Van Goor\, Execu
 tive Director and US Head\, Global Regulatory Policy and Innovation\, Tak
 eda\, Nitender Goyal\, Senior Director Clinical Research\, Alnylam Pharma
 ceuticals\, Sherrita Dorsey\, US Head Patient and Professional Advocacy\,
  Amicus Therapeutics\, Eli Khankin\, Executive Director\, Apellis Pharmac
 euticals\, Rowland Elwell\, Executive Medical Director\, Nephrology Calli
 ditas\, Giorgia Jurisic Snijder\, Director\, Disease Area Expert\, Rare R
 enal\, CSL\, Gabriela Alperovich\, Executive Director\, Medical\, Cardiov
 ascular and Renal\, Global Clinical Lead\, CSL\, Danielle Branch\, Direct
 or\, Patient Advocacy and Community Engagement\, Maze Therapeutics\, Adel
 e Rowley\, Chief Scientific Officer\, Mironid\, Jeff Sands\, Chief Medica
 l Officer\, NephroDI\, Julie Lin\, Senior Vice President\, Clinical Devel
 opment and Drug Safety/ Pharmacovigilance\, Travere Therapeutics\, Joshua
  Waitzman\, Senior Medical Director\, Vera Therapeutics\, Manish Maski\, 
 Executive Director - Global Medical Affairs and Nephrology Lead\, Vertex 
 Pharmaceuticals\, Thomas Miller\, SVP\, Head of Research\, Walden Bioscie
 nces\, Sean Eddy\, Associate Research Scientist\, University of Michigan\
 , Howard Trachtman\, Adjunct Professor\, University of Michigan\, Richard
  Gilbert\, Professor of Medicine\, University of Toronto\, Sorin Fedeles\
 , Executive Director\, Critical Path Institute (C-Path)\, Vincent Ko\, Fo
 under and Executive Director\, KidneyFuture\, Christopher Chen\, Vice Pre
 sident of Research Programs\, PKD Foundation\n\nCategory:&nbsp\;Conferenc
 es | Science\, Health and Medicine | Pharmaceuticals\n\nDate and Time:&nb
 sp\;18th August 2026 at 7:00 am to 20th August 2026 at 5:00 pm\n\nVenue d
 etails:&nbsp\;Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, M
 assachusetts\, 02116\, United States\n
DTEND:20260820T170000
DTSTAMP:20260512T214305Z
DTSTART:20260818T070000
LOCATION:Revere Hotel Boston Common\, 200\, Stuart Street\, Boston\, Massa
 chusetts\, 02116\,
SEQUENCE:0
SUMMARY:The 6th Rare and Genetic Kidney Disease Drug Development Summit is
  the industry's only meeting dedicated exclusively to advancing therapies
  across...
UID:47d95294-e4ac-4a80-ab06-9fccc68b9691
END:VEVENT
END:VCALENDAR